COX19

Across TCGA pan-cancer cohorts, COX19 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated COX19 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher COX19 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated COX19 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where COX19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.540	0.275	.002	14	view →
CCRCC	DFS	Median	III,IV	0.579	0.842	.021	5	view →
LSCC	DFS	Quartile	All	0.882	0.982	.041	4	view →
HNSC	DFS	Quartile	III,IV	0.522	0.842	.006	4	view →
LUAD	OS	Tertile	All	0.999	0.926	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

COX19–PDAC (DFS)

Open the PDAC breakdown →